Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc.

HILS

HILSHillstream BioPharma, Inc. US flag

NASDAQ Capital Market

0.24

USD

+0.01

- -

4.17MMarket Cap

Hillstream BioPharma, Inc.

HILS

(NASDAQ Capital Market)

Recent

price

0.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Innovation Pharmaceuticals Inc. (IPIX)
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
Accustem Sciences Inc. (ACUT)
Zealand Pharma A/S (ZEAL)
HighTide Therapeutics Inc (2511.HK)
Ergomed plc (ERGO.L)
Business: Hillstream BioPharma, Inc. is a biotechnology company focused on developing novel therapeutic candidates targeting oncology and rare immune, inflammatory, and oncological diseases. The company’s core products include proprietary biologics platforms such as Quatramer™, a tumor-targeting nanoparticle drug delivery system; Knob Quatrabodies™ conjugates designed to improve immuno-oncology outcomes; and bi-specific antibodies targeting HER2 and HER3 for solid tumors. Key pipeline candidates include HSB-1940, targeting PD-1 for immuno-oncology applications, and HSB-3215, a bi-specific antibody addressing HER2/HER3-driven cancers. The company also develops early-stage multi-specific biologics using proprietary EpiClick™ Technology and antibody discovery platforms licensed from OmniAb, Inc. Hillstream’s products and technologies aim to enhance targeted cancer therapies with improved binding affinity and minimal off-target toxicity. Hillstream operates primarily in the United States with collaborations intended to expand its immuno-oncology portfolio and solid tumor treatments. Since 2023, Hillstream BioPharma has undergone significant strategic shifts including a corporate name change to Tharimmune, Inc. and a rebranding initiative reflecting its patient-centric focus on immune and inflammatory diseases. The company has actively expanded its oncology pipeline, prioritizing bispecific antibodies and antibody-drug conjugates directed at HER2/HER3 solid tumors, while reinforcing collaborations with Applied Biomedical Science Institute (ABSI) and Minotaur Therapeutics to develop novel biologics against validated targets such as PD-1, HER2, and TROP-2. In 2024, Hillstream (Tharimmune) announced strategic partnerships to expand its therapeutic pipeline for autoimmune diseases and pruritus associated with rare liver diseases. It is progressing towards acquiring clinical-stage assets like TH104, targeting chronic pruritus, and has initiated clinical trials aligned with these assets. The company continues to advance its lead immuno-oncology candidates toward regulatory interactions and clinical development stages, underpinning its transition to a focused cancer biologics and rare disease therapeutics entity. Founded in 2017 and headquartered in Edgewater, New Jersey, Hillstream leverages proprietary antibody engineering technologies including those licensed from OmniAb, such as OmniChicken®, OmniMouse®, OmniFlic®, and OmniTaur™ platforms. These technologies facilitate discovery and development of novel antibodies and multispecific biologics with humanized sequences to target difficult epitopes in cancer and inflammatory pathologies. Hillstream targets biotech and pharmaceutical markets specializing in rare and aggressive solid tumors and autoimmune conditions, seeking to address unmet medical needs through innovation in biologics and nanoparticle delivery systems. Hillstream BioPharma’s recent operational focus highlights transformative collaborations, clinical pipeline advancements, a precise oncology development strategy targeting HER2/HER3 and immune checkpoints, and an organizational redefinition to prioritize patient-focused solutions in immunology and oncology. The company’s evolving asset portfolio and technology platforms position it competitively within the immuno-oncology, inflammation, and rare disease therapeutic sectors. Hillstream BioPharma trades on The Nasdaq Capital Market under the ticker THAR following its name change and corporate repositioning completed in late 2023. The company’s efforts reflect an ongoing strategic expansion across immuno-oncology and rare disease treatment modalities, combining proprietary technology with external partnerships to drive innovation and clinical progress.

Company News